Form 4: Supernus Pharmaceuticals SVP & CFO Timothy Dec Reports Stock Transactions

Timothy Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition and disposal of common stock related to performance share unit settlements.

Summary

• On March 10, 2025, Timothy Dec, the Senior Vice President & CFO of Supernus Pharmaceuticals, engaged in transactions involving the company's common stock.
• Dec acquired 2,000 shares and 1,800 shares of common stock upon the settlement of Performance Share Units granted on February 23, 2023, and February 22, 2024, respectively.
• Simultaneously, Dec disposed of 1,062 shares and 955 shares of common stock to satisfy tax withholding requirements related to the vesting of these Performance Share Units, at a price of $32.06 per share.
• Following these transactions, Dec beneficially owns 12,681 shares of Supernus Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects routine transactions related to executive compensation. The vesting of performance share units is generally a positive sign, but the stock disposal to cover taxes is a standard procedure.

Positives

• The vesting of performance share units suggests that individual performance objectives were met.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be informative for investors.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve a relatively small number of shares.

Key Dates